• Addus HomeCare Corporation recently reported first-quarter 2026 results, with net income rising to US$25.07 million from US$21.23 million and diluted EPS from continuing operations increasing to US$1.36 from US$1.16 a year earlier.
• Growth was led by the Personal Care and Hospice segments, supported by state rate increases, operational efficiencies, and expansion into Indiana through the HomeCourt Home Care acquisition and another pending deal.
• Next, we’ll examine how this Personal Care and Hospice-driven growth, reinforced by recent Indiana acquisitions, affects Addus HomeCare’s existing investment narrative.

Find 51 companies with promising cash flow potential yet trading below their fair value.

Addus HomeCare Investment Narrative Recap

To own Addus, you need to believe in steady, reimbursement-supported growth in Personal Care and Hospice, while accepting real policy and labor risks. The Q1 2026 beat on earnings, driven by these segments and supported by state rate increases, reinforces that core thesis. However, the sharp 7% decline in Home Health revenue keeps the proposed Medicare cuts and segment profitability as the key near term risk to watch, even if this quarter alone does not materially change that risk profile.

Among recent announcements, the company’s ongoing focus on acquisitions, backed by what management calls a supportive capital structure, ties in closely with the Indiana HomeCourt Home Care deal and the pending second acquisition. Together, they highlight how Addus is still leaning into its acquisition-led expansion catalyst, using deals to deepen Personal Care exposure at a time when reimbursement changes and Home Health pressure make disciplined capital deployment especially important.

Yet behind the solid quarter, investors should also be aware that rising labor costs and caregiver shortages could...

Addus HomeCare's narrative projects $1.7 billion revenue and $136.9 million earnings by 2028. This requires 10.1% yearly revenue growth and a $53.9 million earnings increase from $83.0 million.

Uncover how Addus HomeCare's forecasts yield a $142.91 fair value, a 47% upside to its current price.

Exploring Other Perspectives

While consensus focuses on steady growth, the most cautious analysts were assuming only about 4.6% annual revenue growth and US$123.3 million of earnings by 2029, reminding you that views on reimbursement risk and margin pressure can differ widely and that this latest quarter could still shift those expectations in very different directions.

Explore 4 other fair value estimates on Addus HomeCare - why the stock might be worth just $137.61!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Addus HomeCare research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Addus HomeCare research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Addus HomeCare's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.